In one study, Seprafilm® has shown to reduce the extent of pelvic floor adhesions by 69% in radical pelvic surgery1
Prophylactic use of Seprafilm has been shown to reduce the incidence of adhesions and adhesion-related morbidities.2-6 In radical pelvic surgery, including hysterectomy, Seprafilm has been shown to reduce the extent of pelvic floor adhesions by 69% relative to historical controls.1
Seprafilm application sites in total abdominal hysterectomy8:
- Lymph node beds
- Pelvic peritoneal defect
- Abdominal sidewall
- Under abdominal incision
- Remaining adnexa
In a prospective, multicenter, randomized, double-blinded controlled study of patients receiving Seprafilm at open myomectomy, Seprafilm reduced the incidence, severity, and extent of posterior and anterior uterine adhesions. Moreover, 48% of patients treated with Seprafilm were free of adhesions on at least 1 adnexum, compared to only 31% in the untreated control population (P<0.05).3
Seprafilm application sites in myomectomy7:
- Anterior uterus
- Posterior uterus
- Abdominal incision
Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.
Important Safety Information
Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.
Please see full prescribing information.
Bristow RE, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol. 2005;99(2):301-308.
Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183(4):297-306.
Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Fertil: Steril 1996;66(6);904-910.
Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm Adhesion Barrier after intestinal resection. Dis Colon Rectum. 2005;49(1):1-11
Tang C-L, Seow-Choen F, Fook-Chong S, Eu K-W. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision: a prospective randomized trial. Dis Colon Rectum. 2003;46(9):1200-1207.
Kusunoki M, Ikeuchi H, Yanagi H, et al. Bioresorbable hyaluronate-carboxymethylcellulose membrane (Seprafilm) in surgery for rectal carcinoma: a prospective randomized clinical trial. Surg Today. 2005;35(11):940-945.
Seprafilm Adhesion Barrier [package insert]. Cambridge, MA: Genzyme Biosurgery; 2008.
Tabata T, Kihira T, Shiozaki T, et al. Efficacy of a sodium hyaluronate-carboxycellulose membrane (Seprafilm) for reducing the risk of early postoperative small bowel obstruction in patients with gynecologic malignancies. Int J Gynecol Cancer. 2010;20(1):188-193 2010
Beck DE, Cohen Z, Fleshman JW, Kaufman HS, van Goor H, Wolff BG; for Adhesion Study Group Steering Committee. A prospective, randomized, multicenter, controlled study of the safety of Seprafilm® Adhesion Barrier in abdominopelvic surgery of the intestine. Dis Colon Rectum. 2003;46(10):1310-1319.
Seprafilm Placement Video
Watch a demonstration of the quilting technique being used following myomectomy.
To order Seprafilm for your operating room, or to request a product demonstration, call 1-800-261-1570 and select option 1, or fill out an order form.
Order Seprafilm form